Vivesto AB (OASMY)
| Market Cap | 9.48M -26.1% |
| Revenue (ttm) | n/a |
| Net Income | -3.70M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.00 (676.00%) |
| Ex-Dividend Date | Jan 28, 2026 |
| Volume | 1,000 |
| Average Volume | 2,235 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.0001 - 0.0200 |
| Beta | 0.97 |
| RSI | 36.25 |
| Earnings Date | Mar 2, 2026 |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]
News
Vivesto AB (OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise Transcript
Vivesto AB (OTC:OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise November 24, 2025 9:00 AM EST Company Participants Peter Zonabend Erik Kinnmann - Chief E...